Fate Therapeutics, Inc.
FATE · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -8.7% | 17.1% | -12.4% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -1,667% | -1,614.7% | -2,329.5% | -2,268.7% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -1,852.4% | -1,786.6% | -2,309.5% | -2,803.9% |
| EPS Diluted | -0.27 | -0.29 | -0.32 | -0.44 |
| % Growth | 6.9% | 9.4% | 27.3% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |